Related Experiment Video
Updated: May 30, 2026
09:45
Measuring Protein Stability in Living Zebrafish Embryos Using Fluorescence Decay After Photoconversion (FDAP)
Published on: January 28, 2015
Post-production protein stability: trouble beyond the cell factory
Esther Vazquez1, José Luis Corchero, Antonio Villaverde
1Institute for Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
Microbial Cell Factories
|August 3, 2011
Summary
Protein aggregation is a significant challenge in biotechnology and pharmaceuticals, impacting drug safety and efficacy. Protein engineering offers a promising strategy to create more stable therapeutic proteins, improving patient outcomes.
Area of Science:
- Biotechnology
- Pharmaceutical Science
- Protein Engineering
Background:
- Protein function is intrinsically linked to its conformation, making protein aggregation a critical challenge in biotechnological production.
- Aggregation can occur during upstream, midstream, or downstream processing, and even in soluble forms during storage and handling of protein therapeutics.
- Post-production protein aggregation significantly impacts pharmaceutical development by affecting protein stability, pharmacokinetics, bioavailability, immunogenicity, and potential side effects.
Discussion:
- Controlling protein aggregation is crucial for ensuring the safety and efficacy of protein-based drugs.
- The pharmaceutical industry faces considerable challenges in managing protein aggregation in therapeutic formulations.
- Strategies to mitigate aggregation involve both formulation approaches and upstream interventions.
Key Insights:
- Protein aggregation poses a major hurdle in the development and manufacturing of therapeutic proteins.
- The stability and therapeutic value of protein drugs are directly influenced by the degree of aggregate formation.
- Protein engineering presents a viable method to enhance protein stability and therapeutic potential.
Outlook:
- Further research into protein engineering can yield more stable and effective protein drug analogues.
- Optimizing upstream processes through protein engineering can lead to improved therapeutic protein products.
- Developing novel strategies to prevent post-production aggregation will enhance the safety and efficacy of protein-based therapies.
Related Concept Videos
02:11Proteins: From Genes to Degradation
Within a biological system, the DNA encodes the RNA, and the nucleotide sequence in the RNA further defines the amino acid sequence in the protein. This is referred to as “The Central Dogma of Molecular Biology” - a term coined by Francis Crick. Central dogma is a firm principle in biology that defines the flow of genetic information within any life form. The two fundamental steps in central dogma are - transcription and translation.
Transcription is the synthesis of RNA molecules by RNA...
Transcription is the synthesis of RNA molecules by RNA...
02:11Proteins: From Genes to Degradation
Within a biological system, the DNA encodes the RNA, and the nucleotide sequence in the RNA further defines the amino acid sequence in the protein. This is referred to as “The Central Dogma of Molecular Biology” - a term coined by Francis Crick. Central dogma is a firm principle in biology that defines the flow of genetic information within any life form. The two fundamental steps in central dogma are - transcription and translation.
Transcription is the synthesis of RNA molecules by RNA...
Transcription is the synthesis of RNA molecules by RNA...
01:26Bacterial Protein Maturation
Bacterial protein maturation is a tightly regulated process that ensures newly synthesized polypeptides achieve correct functional conformations. This maturation involves a series of modifications, folding events, and quality control steps, often assisted by specialized chaperone proteins.N-Terminal ModificationsThe maturation of bacterial polypeptides begins cotranslationally as the polypeptide exits the ribosome. The first amino acid, N-formylmethionine (fMet), is typically modified at the...
01:53RNA Stability
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
01:53RNA Stability
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
01:26Protein Modifications in the RER
Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal sequences.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal sequences.